



FORM PTO-1449/A and B (Modified)

APPLICATION NO.: 10/821,811

ATTY. DOCKET NO.: P0453.70115US01

FILING DATE: April 8, 2004

CONFIRMATION NO.: 9061

**INFORMATION DISCLOSED
STATEMENT BY APPLICANT**

APPLICANT: Sanghvi et al.

GROUP ART UNIT: 1614

EXAMINER: Not Yet Assigned

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A55	5,804,595		Portoghese, <i>et al.</i>	09-08-1998
	A56	5,866,154		Bahal, <i>et al.</i>	02-02-1999
	A57	2003-0022909	A1	Moss, <i>et al.</i>	01-30-2003
	A58	2003-0124086	A1	Bentley, <i>et al.</i>	07-03-2003
	A59	2003-0191147	A1	Sherman, <i>et al.</i>	10-09-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B28	CA	2,064,373		Lilly (Eli) and Company	09-30-1992	
	B29	EP	506,468	A1	Eli Lilly and Company	09-30-1992	
	B30	EP	643,967	A2	Euro Celtique S.A.	03-22-1995	
	B31	WO	01/32180	A2	Rodeva Limited	05-10-2001	
	B32	WO	02/098422	A1	University of Chicago	12-12-2002	
	B33	WO	03/032990	A2	Shearwater Corporation	04-24-2003	
	B34	WO	2004/014291	A2	Moss	02-19-2004	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C147	FARTHING et al., New drugs in the management of the irritable bowel syndrome. <i>Drugs</i> . 1998 Jul;56(1):11-21. Review.		
	C148	FINGL et al., Chapter 43: Laxatives and cathartics. <i>In Pharmacological Basis of Therapeutics</i> . 1980: 1002-5.		
	C149	SCHUBERT-ZSILAVECZ et al., Das reizdarmsyndrom irritable bowel syndrome. <i>Deutsche apotheker zeitung</i> . 2002 Aug 22; 142(34): 40-9.	Yes	
	C150	TALLEY et al., Pharmacologic therapy for the irritable bowel syndrome. <i>Am J Gastroenterol</i> . 2003 Apr;98(4):750-8. Review.		
	C151	THOMPSON et al., Laxatives: clinical pharmacology and rational use. <i>Drugs</i> . 1980 Jan;19(1):49-58. Review.		

EXAMINER:

/Donna Jagoe/

DATE CONSIDERED:

9/21/2008

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./ (09/21/2008)